The Food and Drug Administration has approved a drug that reduces the chances of contracting HIV. A University of Utah ...

Clinical trials showed 99.9% of participants who received the drug, called Yeztugo​ from company Gilead Sciences, remained ...

The Food and Drug Administration has approved a new drug that could prevent HIV infections with just two shots every year and ...

Yeztugo, a twice-a-year antiviral shot to prevent HIV, was approved by the Food and Drug Administration on Wednesday, marking ...

A drug currently used to treat certain HIV infections has also, on Wednesday, received approval from the US Food and Drug ...

HealthLink talked with a Seattle-based physician about why the newly approved drug could be a game-changer in preventing HIV.

Lenacapavir, the injectable drug developed by a US-based company, Gilead Sciences, was trialled (tested) in Uganda and South ...

Is the cost of research aimed at curing HIV worth it, when HIV can be effectively managed and prevented by existing drugs?

In clinical trials, researchers found Yeztugo to be highly effective as a twice-yearly form of pre-exposure prophylaxis.

Yeztugo, approved by the FDA, was highly effective in two randomized trials. It costs $28,218 per year, and people have to be HIV-negative to get it.

WASHINGTON -- The U.S. has approved the world’s only twice-a-year shot to prevent HIV, maker Gilead Sciences announced ...

A drug called lenacapavir, administered in two injections a year, offers protection from HIV comparable to daily pills. One ...